Abstract A007: Methyl jasmonate and finasteride synergistically reduce testosterone-induced benign prostatic hyperplasia through regulation of inflammatory and apoptotic processes in rats

Abstract

Abstract Background: Phytotherapy is becoming a treatment option in management of diseases, including benign prostatic hyperplasia (BPH). We have shown previously that methyl jasmonate (MeJA) ameliorated BPH; however, the underlying mechanism of action remains unknown. This study was designed to investigate in mechanistic terms the protective role of MeJA in BPH. Methods: BPH was induced by daily injections of testosterone propionate (TP) (3 mg/kg) for 28 days. Results: The weight and organo-somatic weight of prostate in BPH rats were 6.8 and 5.1 times higher than castrated-control group, respectively. Inflammatory markers, prostatic myeloperoxidase,and total nitric oxide were significantly increased in BPH group. The activity of aniline hydroxylase (Phase I drug metabolizing enzyme) was significantly increased in BPH rats by 22%. In BPH group, immunohistochemistry revealed strong expression of prostatic inducible nitric oxide synthase, cyclooxygenase-2 and Bcl2, while mild expression of p53 and Bax WAS seen. Serum triglyceride and total cholesterol were significantly increased, while HDL-c was decreased in BPH. Interestingly, MeJA and finasteride (singly or combination) attenuated inflammatory and apoptotic indices in BPH rats. Conclusion: MeJA and finasteride synergistically protect against TP-induced BPH via mechanisms that involve antiinflammation, induction of apoptosis, and inhibition of phase I drug metabolizing enzyme. Citation Format: Oluwatosin A. Adaramoye, Solomon E. Owumi, Olubukola Akanni, Oluwabunmi E. Olapade-Olaopa, Olusoji J. Abiola, Oluyemi Akinloye. Methyl jasmonate and finasteride synergistically reduce testosterone-induced benign prostatic hyperplasia through regulation of inflammatory and apoptotic processes in rats [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr A007.